Date: **August 12, 2026**

To,
Manager,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 533315

Dear Sir/Madam,

Sub: Investor Presentation

With reference to the subject, please find enclosed the Investor Presentation for the quarter ended June 30, 2026.

Kindly take the above information on record.

Thanking You,

Yours faithfully,

For Innovassynth Technologies (India) Limited
(Formerly known as Innovassynth Investments Limited)

SAMEER SALIM PAKHALI
Digitally signed by SAMEER SALIM PAKHALI
Date: 2026.08.12 19:47:36 +05'30'

Sameer Pakhali
Company Secretary & Compliance Officer
ACS 55746

INNOVASSYNTH

Investor Presentation Q1FY27

12-August-2026

Chemistry of possibilities

Disclaimer

*“This presentation has been prepared by Innovassynth Technologies (India) Limited (“**Company**”) (formerly known as Innovassynth Investments Limited).*

The presentation aims to cover key financial and business highlights. This presentation and some statements herein may be forward-looking statements and may not be based on historical information or facts and may be expressed in good faith and in the Company’s management’s opinion reasonable, including those relating to the Company’s general business plans and strategy, its growth prospects and its competitive and regulatory environment. These statements are inherently subject to a variety of risks, uncertainties, and assumptions that could cause actual results to differ materially from those projected based on risks relating to the execution, global supply chain, technological developments, geopolitical developments, etc. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. This presentation does not aim to offer, and should not be viewed as providing, a complete or comprehensive assessment of the Company’s business, financial performance, operating results, market position, or prospects. Furthermore, this presentation is not an offer, solicitation, or invitation to buy or subscribe for any securities of the Company.”

Executive Summary and Financials

Executive Summary

Performance Update and Outlook

- Despite continued logistics-related challenges, we delivered an improvement in revenue and EBIDTA during the quarter, with margins improving both sequentially and year-on-year.
- Customer demand remains healthy, supported by continued business from existing customers and new business opportunities.
- The order book stood at Rs 165 crore as of 30th June 2026, providing healthy revenue visibility for the coming quarters.
- Several customer molecules are progressing through different stages of development and commercialization, with some programs moving closer to commercial production. This progress has the potential to translate into additional volumes and contribute to future revenue growth.
- With improving operating performance, a healthy order book and continued progress across customer programs, we remain confident of sustained improvement in business performance.

Strong execution and customer demand continue to drive profitability improvement and support future growth visibility.

Executive Summary

Execution Highlights & Growth Drivers

- Life Sciences capacity expansion remains on track, with the planned addition expected to double capacity and support anticipated growth in CRDMO demand.
- A strong quality track record was maintained through successful customer audits with no major observations, reinforcing the robustness of our quality systems and compliance framework.
- CRDMO customer engagement in Lifesciences continues to strengthen, with ongoing projects, repeat business and a healthy pipeline of new opportunities reflecting strong execution capabilities and customer confidence.
- A diversified customer base across the USA and Europe, supported by a robust project pipeline, provides a balanced platform for sustainable growth and reduces geographic concentration risk.
- Operational efficiency initiatives are progressing well, improving cost competitiveness and margins, while capacity expansion, strong customer relationships and a healthy CRDMO pipeline provide good visibility for sustained medium-term growth.

With capacity expansion progressing as planned, a strong quality track record, deepening customer engagement and a healthy project pipeline, the Company remains well positioned to deliver sustainable growth and improved profitability over the medium term.

Strategic Growth & Business Development Highlights

Open Order Book

Amount in INR Crores

Life Sciences	Specialty Chemicals	CDMO	Grand Total
INR ~84	**INR ~15**	**INR ~66**	**INR ~165**
Major orders from USA/EU based companies, with additional orders expected	Strong portfolio and custom product	Confirmed requirements shared by large global company	

Key Focus Areas

Dedicated focus on Lifesciences and Spec Chem, custom and portfolio products with a defined cadence

Effective order execution and scale-up to improve process efficiency and operational excellence

Successful completion of several audits could result into improved customer confidence

Profit and Loss Statement

Particulars	Quarter Ended			Year Ended
	30 June-2026	31-Mar-2026	30-June-2025	31-Mar-2026
Revenue from operations	5,599	5,083	1,227	10,235
Operating Expenses	(4,102)	(4,455)	(2,780)	(12,677)
EBIDTA	**1,497**	**628**	**(1,553)**	**(2,442)**
EBIDTA Margin (%)	27%	12%	-127%	-24%
Depreciation and Amortisation	(200)	(197)	(195)	(788)
Finance Cost	(200)	(223)	(135)	(723)
Other Income	19	12	9	61
Profit/(loss) before exceptional items and tax	**1,116**	**221**	**(1,875)**	**(3,892)**
Exceptional items	-	11	(0)	82
Profit/(loss) before tax	**1,116**	**210**	**(1,875)**	**(3,974)**
Tax expenses/(credit)	442	(985)	(8)	(1,095)
PAT	674	1,195	(1,867)	(2,879)
PAT Margin %	12%	24%	-152%	-28%
Other Comprehensive Income	-	15	-	30
Total Comprehensive Income	**674**	**1,210**	**(1,867)**	**(2,848)**
Diluted EPS (INR)	0.80	1.58	(2.47)	-3.82

Amount in INR Lakhs

Company Overview

Business Model

Innovassynth has 3 business units

Life Sciences & Nucleosides

Specialty Chemicals

Contract Research Development and Manufacturing

Exports Led Business : ~90% of revenue from global geographies with key focus on USA & EU

Our Life Sciences & Specialty Chemicals segments focus on developing niche products for customers, resulting in higher profit margins

State of the art manufacturing facility

Integrated Manufacturing Facility at Khopoli, near Mumbai, India

9 multipurpose manufacturing plants built to handle a wide range of chemical processes and production scales

CRDMO - Our comprehensive CRDMO services, from concept to commercialization

- Custom Research
- Contract Manufacturing
- Full Time Equivalent/Fee for Service
- Scale up to Commercial Products

- 50+ highly qualified scientists specializing in specialty intermediates, bulk chemicals for various applications
- Custom development and manufacturing as per customer requirements

Innovassynth – At a Glance



- Manufacturing plant in 60+ acres at Khopoli with 8 units
- 10+ Line with total reaction capacity of **250 KL+**
- **50L** to 10KL reactor sizes

- 60 fume hoods catering to custom development for FTE/FFS
- Dedicated analytical lab

- Equipment of various MOC : SSR, MSGLR, Glass AR
- ANF, ANFD, Centrifuge, Vacuum and Rotary Tray dryers
- Utilities to handle large scale and range

- Pharmaceuticals
- Diagnostics
- Electronics
- Flavours and Fragrances
- Semiconductors
- Polymers

- Total Strength : 300+
- 50+ Scientists, 10+ PhDs and 50+ technical staff
- Skilled team of engineers and support staff

- Oxidation, reduction, rearrangement reactions
- Friedel-crafts, homologation, Diels Alder, Diazotation, Suzuki
- Cryogenic reactions involving Grignard, n-BuLi, MeLi

Consistently Improving:Quality, Safety, Sustainability

ISO 27001:2022,
ISO 14001:2015,
ISO 45001:2018,
ISO 9001:2015

Ecovadis Gold Rating for the second consecutive year

SBTi and **Responsible Care** initiated in 2026

Preparedness and Training

- **Structured safety induction** for all workforce segments
- Recurring **EHS capability-building programs**
- **HAZOP embedded** into all scale-up workflows
- Periodic **emergency simulations** validating response readiness

Safety & Environmental Infrastructure

- **260 KL ETP** enabling compliant wastewater treatment
- **740 KL ZLD** system supporting sustainability goals
- **Integrated fire systems** (hydrants, DCP/CO_2/foam)
- Emergency sirens, eye wash stations & body showers

Health & Continuous Monitoring

- **24/7 Occupational Health Centre** with bed, creche & ambulance
- Annual & semi-annual **medical surveillance programs**
- Real-time **online monitoring** of boiler & process stacks
- Staff trained **in Emergency Procedures and First-Aid**

Capital Market Information





Price Data as on 30-Jun-26	INR
Face Value	10
Market Price	129.26
52 Week H/L	135.85/44.99
Market Cap (Cr)	1261.51
Equity Shares Outstanding (# Cr)	9.28

INNOVASSYNTH

Thank You